Some relief for industry as French reform bill nears final approval
This article was originally published in Scrip
Executive Summary
The French bill on reforming the drug regulatory system is nearing final approval, offering industry the prospect of tougher obligations regarding comparative trials, side-effect reporting, benefit-risk monitoring and the declaration of links with its stakeholders such as doctors and patient groups.